Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
2017 ◽
Vol 390
(10102)
◽
pp. 1585-1594
◽
Keyword(s):
Phase 3
◽